Treatment strategies in patients without an HLA identical sibling
| Treatment . | <20 y . | 20-40 y . | 40-60 y . | >60 y . |
|---|---|---|---|---|
| First line | hATG + CsA or UD Tx | hATG + CsA and UD search | hATG + CsA and UD search | hATG + CsA |
| Second line | UD Tx | UD Tx | UD Tx or rATG + CsA | hATG + CsA or EPAG |
| Other treatment | HAPLO Tx | HAPLO Tx | +EPAG | +EPAG |
| +Androgens | +Androgens | |||
| +Clinical trials | +Clinical trials |
| Treatment . | <20 y . | 20-40 y . | 40-60 y . | >60 y . |
|---|---|---|---|---|
| First line | hATG + CsA or UD Tx | hATG + CsA and UD search | hATG + CsA and UD search | hATG + CsA |
| Second line | UD Tx | UD Tx | UD Tx or rATG + CsA | hATG + CsA or EPAG |
| Other treatment | HAPLO Tx | HAPLO Tx | +EPAG | +EPAG |
| +Androgens | +Androgens | |||
| +Clinical trials | +Clinical trials |
CsA, cyclosporine; EPAG, eltrombopag; HAPLO Tx, related HLA haploidentical transplant; hATG, horse anti-thymocyte globulin; rATG, rabbit ATG; UD Tx, unrelated donor transplant.